Compare MasterCard Inc (MA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? MasterCard Inc trades at $585.89 (market cap $503.50B), while Vertex Pharmaceuticals Incorporated trades at $510.72 (market cap $127.55B). The key difference: MasterCard Inc is far larger — about 3.9× Vertex Pharmaceuticals Incorporated's market cap, and MasterCard Inc pays a 0.61% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 134 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| MA | VRTX | |
|---|---|---|
Market Cap | $503.50B | $127.55B |
Volume | 3,390,859 | 1,487,944 |
Sector | Financials | Health |
52-Week High | $599.86 | $557.96 |
52-Week Low | $471.55 | $407.37 |
Typical Hold Time | 134 Days | 120 Days |
Enterprise Value | $516.53B | $121.68B |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $585.52, up 2.71% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 2025 revenue of $32.79B, net income margin of 46.34%, and impressive ROE of 241.49%. Recent institutional buying activity and positive analyst sentiment (80% buy ratings) support the stock's momentum as it approaches key resistance levels.
Mastercard presents a compelling growth opportunity with expanding digital payment adoption and strong financial performance, though elevated valuation multiples (P/E 31.6, P/S 14.7) and emerging payment technology competition warrant monitoring. The consensus price target of $666.67 suggests 14% upside potential from current levels.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
